These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17124594)

  • 1. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
    Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
    Zopf S; Neureiter D; Bouralexis S; Abt T; Glaser KB; Okamoto K; Ganslmayer M; Hahn EG; Herold C; Ocker M
    Int J Oncol; 2007 Dec; 31(6):1391-402. PubMed ID: 17982666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL; Van Quill KR; O'Brien JM
    Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
    Monks A; Hose CD; Pezzoli P; Kondapaka S; Vansant G; Petersen KD; Sehested M; Monforte J; Shoemaker RH
    Anticancer Drugs; 2009 Sep; 20(8):682-92. PubMed ID: 19606018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
    Flis S; Gnyszka A; Flis K; Spławiński J
    Eur J Pharmacol; 2010 Feb; 627(1-3):26-32. PubMed ID: 19853597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
    Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
    Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
    Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
    Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
    Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
    Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
    Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.